---
document_datetime: 2025-10-30 10:00:23
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/palonosetron-accord-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: palonosetron-accord-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7144468
conversion_datetime: 2025-12-24 22:40:52.811631
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Palonosetron Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 28/10/2025                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296285   | PL   |
|---------------------|------|

<div style=\"page-break-after: always\"></div>

| the active substance - B.I.c.1.a Qualitative and/or quantitative composition - Accepted  B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted  B.I.b.2 Change in test procedure for active   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minor change to the restricted part of an Active Substance Master File - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   |            |             |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Article 61(3) / EMA/N/0000221332      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet to include the list of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12/07/2024 | PL          |
| Variation type IB / EMA/VR/0000171902 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted To update the package leaflet to align with the user testing assessment for the                                                                                                                                                | 03/04/2024 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| reference product. The MAH also took this opportunity to correct the SmPC section 4.8 to reflect the QRD recommended reference to appendix V in the reporting of suspected adverse reactions.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|